Study S001568

A Multicenter, Randomized, Open-label, Treatment Switching Phase II Study to Evaluate the Efficacy and Safety of XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07073417
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: NONE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 163
Start: 2025-07-28
Primary completion: 2027-02-27
Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Conditions: Obesity; Weight Management
Interventions: DRUG:XW003 injection; DRUG:semaglutide injection
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight relative to baseline [week 48]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0053457	2849-LB: Efficacy and Safety of cAMP-Biased Ecnoglutide vs. Unbiased Semaglutide in Adults with Obesity: Twenty-Week Results from a Multicenter, Randomized, Open-Label, Phase 2 Study LINONG JI, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT07073417